Doxifluridine

Overview of the chemotherapeutic agent Doxifluridine

Doxifluridine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Doxifluridine is an oral prodrug of the chemotherapeutic agent 5-fluorouracil (5-FU), used in the treatment of various cancers. It is designed to enhance the delivery and efficacy of 5-FU by being converted into the active drug within the body.

Mechanism of Action

Doxifluridine is metabolized into 5-fluorouracil by the enzyme thymidine phosphorylase, which is often found in higher concentrations in tumor tissues compared to normal tissues. This selective activation allows for higher concentrations of the active drug in cancerous tissues, potentially reducing systemic toxicity.

Pharmacokinetics

Doxifluridine is administered orally and is absorbed through the gastrointestinal tract. Once absorbed, it is converted into 5-fluorouracil in the liver and tumor tissues. The conversion process is facilitated by the presence of thymidine phosphorylase, which is more abundant in tumor cells, thus providing a targeted approach to chemotherapy.

Clinical Use

Doxifluridine is primarily used in the treatment of colorectal cancer, breast cancer, and gastric cancer. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug's ability to be selectively activated in tumor tissues makes it a valuable option in cancer therapy.

Side Effects

As with many chemotherapeutic agents, doxifluridine can cause a range of side effects. Common side effects include nausea, vomiting, diarrhea, and myelosuppression. Due to its selective activation, it may have a more favorable side effect profile compared to direct administration of 5-fluorouracil.

Related pages

• 5-fluorouracil
• Chemotherapy
• Cancer treatment

• 

  Doxifluridine